Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Recurium Ip Holdings LLC currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 2 distinct art units. This indicates that each of the 3 pending office actions is being handled by a different examiner, providing a variety of perspectives on the company's pharmaceutical innovations.
The busiest examiner, HEITMEIER, KENDALL NICOLE, is responsible for 1 pending office action. Since the total number of pending office actions is 3, and there are 3 distinct examiners, each examiner is managing exactly 1 case. This distribution across 2 distinct art units suggests that the company's filings are concentrated in specific areas of biotechnology rather than being widely scattered.
Practitioners should note that the 3 pending office actions require individual attention due to the lack of examiner overlap. With 3 distinct examiners involved, there is no opportunity to leverage a single examiner's familiarity with the portfolio across multiple cases. However, the use of 2 distinct art units for the 3 pending office actions may offer some consistency in the broader examination standards applied to the Biotechnology & Pharmaceuticals filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| §103 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634055 | COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES | HEITMEIER, KENDALL NICOLE | — |
| 18389654 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | SHOWALTER, ALEXANDER KEITH | — |
| 17998561 | MONO- AND COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634055 | COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES | HEITMEIER, KENDALL NICOLE | — |
| 18389654 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | SHOWALTER, ALEXANDER KEITH | — |
| 17998561 | MONO- AND COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634055 | COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES | HEITMEIER, KENDALL NICOLE | 1621 | §101§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18389654 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | SHOWALTER, ALEXANDER KEITH | 1629 | §101§103§112Other | Non-Final OA | — | Pending | Dec 19, 2023 |
| 17998561 | MONO- AND COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial